58 results on '"Grothey, Axel"'
Search Results
2. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
3. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
4. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
5. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
6. Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)
7. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
8. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials
9. THERAPY: Colorectal cancer: how to teach an old drug new tricks
10. Metastatic extramammary Pagetʼs disease responding to weekly paclitaxel
11. ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer
12. The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer
13. GASTROINTESTINAL CANCER: Rationale for metronomic chemotherapy in phase III trials
14. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers
15. COLORECTAL CANCER IN 2014: Progress in defining first-line and maintenance therapies
16. Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
17. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study†
18. Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147
19. The search for treatments to reduce chemotherapy-induced peripheral neuropathy
20. Drug rechallenge and treatment beyond progression—implications for drug resistance
21. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement
22. Treatment options for advanced pancreatic cancer: a review
23. Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer: A Randomized Trial
24. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: Results from a large prospective observational cohort study (BRiTE)
25. Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer
26. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online
27. Biomarkers and surrogate end points —the challenge of statistical validation
28. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
29. A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
30. Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer
31. Targeting the Right Target: Epidermal Growth Factor Receptor-Directed Individualized Therapy
32. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
33. Do All Patients with Metastatic Colorectal Cancer Need Chemotherapy Until Disease Progression?
34. Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
35. Neoadjuvant Therapy With Bevacizumab
36. First- and second-line therapy of metastatic colorectal cancer
37. Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer
38. Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?
39. Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line
40. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
41. Enhancing Oxaliplatin-Based Regimens in Colorectal Cancer by Inhibiting the Epidermal Growth Factor Receptor Pathway
42. Clinical Management of Oxaliplatin-Associated Neurotoxicity
43. N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer
44. Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab
45. FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer
46. Clinical Management of Oxaliplatin-Associated Neurotoxicity
47. Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy
48. Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting
49. Clinical Trial Designs for Prospective Validation of Biomarkers
50. Developments in combination chemotherapy for colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.